Brief: Cogent Biosciences Announces Planned 2024 Milestones For Bezuclastinib And Emerging Portfolio Of Selective And Potent Targeted Therapeutics

Cogent Biosciences

09/01/2024 14:16

Jan 9 (Reuters) - Cogent Biosciences Inc  COGT.O :
    * COGENT BIOSCIENCES ANNOUNCES PLANNED 2024 MILESTONES FOR
BEZUCLASTINIB AND EMERGING PORTFOLIO OF SELECTIVE AND POTENT
TARGETED THERAPEUTICS
    * COGENT BIOSCIENCES - PLAN TO INITIATE PHASE 1 TRIAL OF
CGT4859,
A POTENTIAL BEST-IN-CLASS, POTENT, SELECTIVE AND REVERSIBLE
FGFR2 INHIBITOR IN 2H 2024
    * COGENT BIOSCIENCES INC - ON TRACK TO COMPLETE ENROLLMENT
IN
REGISTRATION-DIRECTED PHASE 2 APEX STUDY OF BEZUCLASTINIB IN
ADVSM PATIENTS BY END OF 2024
    * COGENT BIOSCIENCES INC - PLAN TO INITIATE GLOBAL,
REGISTRATION-DIRECTED SUMMIT PART 2 STUDY OF BEZUCLASTINIB IN
NONADVSM PATIENTS DURING 1H 2024

Source text for Eikon:  ID:nGNX47zR5m 
Further company coverage:  COGT.O 

 (Reuters.Briefs@thomsonreuters.com)